Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hauswald, Henrik [VerfasserIn]   i
 Jensen, Alexandra [VerfasserIn]   i
 Krauß, Jürgen [VerfasserIn]   i
 Haselmann, Renate [VerfasserIn]   i
 Lossner, Karen [VerfasserIn]   i
 Münter, Marc [VerfasserIn]   i
 Debus, Jürgen [VerfasserIn]   i
Titel:Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx
Verf.angabe:H. Hauswald, A. D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M. W. Münter, J. Debus
E-Jahr:2018
Jahr:November 2018
Umfang:10 S.
Fussnoten:Gesehen am 20.12.2018
Titel Quelle:Enthalten in: Clinical and translational radiation oncology
Ort Quelle:Amsterdam : Elsevier, 2016
Jahr Quelle:2018
Band/Heft Quelle:13(2018), Seite 64-73
ISSN Quelle:2405-6308
Abstract:Purpose: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx. Methods: In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm consisted of a combined induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, followed by bioradiation with the monoclonal antibody cetuximab, carbon ion boost (24Gy(RBE) in 8 fractions) and IMRT (50Gy in 25 fractions). The trial was closed early due to slow accrual. Results: Eight patients (median age 52.5years) were enrolled into the trial. The median follow-up was 13months and the 12-months locoregional tumor control, progression-free survival and overall survival rates were 100.0% each. Complete remission was achieved in 7 patients. The most commonly late radiation adverse event was xerostomia (85.7% at 12months). Five serious adverse events with recovery were documented in 4 patients: mucositis grade 3 (n=2), decreased lymphocyte count grade 4, febrile neutropenia grade 4 and hypersensitivity grade 3 to cetuximab (n=1 each). Most symptom scales had their worst value at the last treatment day and recovered until the 4th follow-up visit. Conclusion: The study treatment was tolerable and promising. Reduced quality of life recovered for most aspects until the last follow-up visit.
DOI:doi:10.1016/j.ctro.2018.09.005
URL:kostenfrei: Volltext ; Verlag: http://dx.doi.org/10.1016/j.ctro.2018.09.005
 kostenfrei: Volltext: http://www.sciencedirect.com/science/article/pii/S240563081830065X
 DOI: https://doi.org/10.1016/j.ctro.2018.09.005
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Carbon ion therapy
 Cetuximab
 Head and neck cancer
 LAHNC
 Particle therapy
 SCCHN
K10plus-PPN:1585802867
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68342840   QR-Code
zum Seitenanfang